Two Cases of Sinusitis Induced by Immune Checkpoint Inhibition

J Immunother. 2017 Oct;40(8):312-314. doi: 10.1097/CJI.0000000000000174.

Abstract

We report the acute onset of aseptic sinusitis in 2 patients receiving the immune checkpoint inhibitors, ipilimumab and nivolumab, for treatment of metastatic melanoma. Ipilimumab, a monoclonal antibody targeting cytotoxic T-lymphocyte antigen-4, and nivolumab, targeting programmed cell death-1, have been associated with numerous immune-related adverse events. To the authors' knowledge, this is the first report of aseptic sinusitis as a consequence of immune checkpoint inhibition therapy.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab / therapeutic use
  • Adult
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Atrial Fibrillation / diagnosis*
  • Atrial Fibrillation / etiology
  • Atrial Fibrillation / prevention & control
  • CTLA-4 Antigen / immunology
  • Drug-Related Side Effects and Adverse Reactions / diagnosis*
  • Drug-Related Side Effects and Adverse Reactions / prevention & control
  • Humans
  • Immunotherapy / adverse effects
  • Immunotherapy / methods*
  • Ipilimumab / adverse effects
  • Ipilimumab / therapeutic use*
  • Male
  • Melanoma / diagnosis*
  • Melanoma / drug therapy
  • Neoplasm Metastasis
  • Nivolumab
  • Programmed Cell Death 1 Receptor / immunology
  • Remission Induction
  • Sinusitis / diagnosis*
  • Sinusitis / etiology
  • Sinusitis / prevention & control
  • Tumor Necrosis Factor-alpha / immunology
  • Withholding Treatment

Substances

  • Antibodies, Monoclonal
  • CTLA-4 Antigen
  • Ipilimumab
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Tumor Necrosis Factor-alpha
  • Nivolumab
  • Adalimumab